Intracavernous pharmacotherapy

World Journal of Urology

Volumn 15, Issue 1, 1997, Pages 71-77

  Truss, Michael C ^a   Becker, Armin J ^a   Schultheiss, Dirk ^a   Jonas, Udo ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VASODILATOR AGENT;

ANIMAL; HUMAN; IMPOTENCE; INTRAVENOUS DRUG ADMINISTRATION; MALE; REVIEW;

ANIMALS; HUMANS; IMPOTENCE; INJECTIONS, INTRAVENOUS; MALE; VASODILATOR AGENTS;

EID: 0030640143     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01275160     Document Type: Article

References (110)

1. Adaikan PG, Kottegoda SR, Ratnam SS ( 1986) A possible role for prostaglandin E1 in human penile erection. Proceedings, 2nd world meeting on impotence, Prague, October 13, 1986
2. Althof SE, Turner LA, Levine SB, Risen C, Kursh ED, Bodner D, Resnick M (1987) Intracavernosal injection in the treatment of impotence: a prospective study of sexual, psychological, and marital functioning. J Sex Marital Ther 13: 155-167
3. Althof SE, Turner LA, Levine SB, Risen C, Kursh E, Bodner D, Resnick M (1989) Why do so many people drop out from auto-injection therapy for impotence? J Sex Marital Ther 15: 121-129
4. Andersson KE (1994) Pharmacology of erection: agents which initiate and terminate erection. Sex Disabil 12: 53-79
5. Andersson KE, Holmquist F (1994) Regulation of tone in penile cavernous smooth muscle. Established concepts and new findings. World J Urol 12: 149-261
6. Andersson KE, Wagner G (1995) Physiology of penile erection. Pharmacol Rev 75: 191-236
7. Armstrong DK, Convery A, Dinsmore WW (1993) Intracavernosal papaverine and phentolamine for the medical management of erectile dysfunction in a genitourinary clinic. Int J Std Aids 4: 214-216
8. Armstrong DK, Convery AG, Dinsmore WW (1994) Reasons for patient drop-out from an intracavernous auto-injection programme for erectile dysfunction. Br J Urol 74: 99-101
9. Bennett AH, Carpenter AJ, Barada JH (1991) An improved vasoactive drug combination for pharmacological erection program. J Urol 146: 1564-1568
10. Beretta G, Zanollo A, Fanciullacci F, Catanzaro F(1986) Intracavernous injection of papaverine in paraplegic males. Acta Eur Fertil 17: 283-284
11. Beretta G, Zanollo A, Ascani L, Re B (1989) Prostaglandin El in the therapy of erectile deficiency. Acta Eur Fertil 20: 305-308
12. Bodner DR, Lindan R, Leffler E, Kursh ED, Resnick MI (1987) The application of intracavernous injection of vasoactive medications for erection in men with spinal cord injury. J Urol 138: 310-311
13. Brading AF, Burdygat THV, Scipnyuk ZD (1983) The effects of papaverine on the electrical and mechanical activity of the guinea-pig ureter. J Physiol (Lond) 334: 79-89
14. Brindley GS (1983) Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence. Br J Psychiatry 143: 332
15. Brindley GS (1986) Maintenance treatment of erectile impotence by cavernosal unstriated muscle relaxant injection. Br J Psychiatry 149: 210-215
16. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH (1992) Nitric oxide: a physiologic mediator of penile erection. Science 257: 401-03
17. Buvat J, Lemaire A, Marcolin G, Dehane JL, Buvat-Herbaut M (1987) Intracavernous injection of papaverine (ICIP). Assessment of its diagnostic and therapeutic value in 100 impotent patients. World J Urol 5: 150-155
18. Buvat J, Lemaire A, Buvat HM, Marcolin G (1989) Safety of intracavernous injections using an alpha-blocking agent. J Urol 141: 1364-1367
19. Cahn D, Melman A, Valcic M, Christ GJ (1996) Forskolin: a promising new adjunct to intracavernous pharmacotherapy. J Urol 155: 1789-1794
20. Cavallini G (1991) Minoxidil versus nitroglycerin: a prospective double-blind controlled trial in transcutaneous erection facilitation for organic impotence. J Urol 146: 50-53
21. Collins J, Thijssen A (1993) Experience with intracorporal prostaglandin E1, papaverine and phentolamine in patients with erectile dysfunction. J Urol 149: 345A
22. Delcour C, Wespes E, Vandenbosch G, Struyven SCCJ (1987) The effect of papaverine on arterial and venous hemodynamics of erection. J Urol 138: 187-189
23. Derouet H, Caspari D, Munch M, Ziegler M (1991) [Acceptance of corpus cavernosum auto-injection therapy in long-term treatment of erectile dysfunction] Urologe [A] 30: 423-427
24. Dilworth JP, Lewis RW (1991) The use of multicomponent injection agents in the diagnosis and treatment of impotence. J Urol 145: 232A
25. Djamilian M, Stief CG, Kuczyk M, Jonas U (1993) Followup results of a combination of calcitonin gene-related peptide and prostaglandin E1 in the treatment of erectile dysfunction. J Urol 149: 1296-1298
26. Domer FF, Wessler G, Brown RL, Charles HC (1978) Involvement of the sympathetic nervous system in the urinary bladder internal sphincter and in penile erection in the anesthetized cat. Invest Urol 15: 404-407
27. Fahrenkrug J (1989) VIP and autonomic neurotransmission. Pharmacol Ther 41: 515-534
28. Fallon B (1995) Intracavernous injection therapy for male erectile dysfunction. Urol Clin North Am 22: 833-845
29. Gall H, Sparwasser C,Bahren W, Scherb W, Holzki G, Irion R (1992) [Long-term results of corpus cavernosum auto-injection therapy in treatment of patients with chronic erectile dysfunction], Urologe [A] 31: 31-36
30. Gerstenberg TC, Metz P, Ottesen B, Fahrenkrug J(1992) Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure. J Urol 147: 1277-1279
31. Giraldi A, Wagner G (1990) Effect of pinacidil upon penile erectile tissue in vitro and in vivo. Pharmacol Toxicol 67: 235-238
32. Gloub M, Zia P, Mastsuno M (1975) Metabolism of prostaglandins A and E1 in man. J Clin Invest 56: 1404-1410
33. Goldstein I, Borges FD, Fitch WP, Kaufman J, Damron K, Moreno J, Payton T, Yingst J, Krane RJ (1990) Rescuing the failed papaverine/phentolamine erection: a proposed synergistic action of papaverine, phentolamine and prostaglandin E1. J Urol 143: 304A
34. Hellstrom WJG, Wang R, Kadowitz PJ. Domer FR (1992) Potassium channel agonists cause penile erection in cats. Int J Impotence Res 4: 35-43
35. Hollander JB, Gonzalez J, Norman T (1992) Patient satisfaction with pharmacologic erection program. Urology 39: 439-441
36. +-channel openers for relaxation of isolated penile erectile tissue from rabbit. J Urol 144: 146-151
37. Holmquist F, Andersson KE, Hedlund H (1990) Effects of pinacidil on isolated human corpus cavernosum penis. Acta Physiol Scand 138: 463-469
38. Holmquist F, Hedlund H, Andersson KE (1991) L-NG-nitro arginine inhibits non-adrenergic, non-cholinergic relaxation of human isolated corpus cavernosum. Acta Physiol Scand 141: 441-442
39. Holmquist F, Hedlund H, Andersson KE (1992) Characterization of inhibitory neurotransmission in the isolated corpus eavernosum from rabbit and man. J Physiol Lond 449: 295-311
40. Huddart H, Langton P, Saad KHM (1984) Inhibition of papaverine of calcium movements and tension in the smooth muscle of rat vas deferens and urinary bladder. J Physiol 349: 189-194
41. Hwang TI, Yang CR, Wang SJ, Chang CL, Tzai TS, Chang CH, Wu HC (1989) Impotence evaluated by the use of prostaglandin E1. J Urol 141: 1357-1359
42. Ignarro LJ, Byrns RE, Buga CM, Wood KS (1987) Endot-helium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 61: 866-879
43. Ignarro LJ, Bush PA, Buga GM, Woods KS, Fukuto JM, Rajfer J (1990) Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus eavernosum smooth muscle. Biochem Biophys Res Comm 170: 843-850
44. Imagawa A, Kimura K, Kawanishi Y, Tamura M (1989) Effect of moxisylyte hydrochloride on isolated human penile corpus caverosum tissue. Life Sci 44: 619-623
45. Irwin MB, Kata EJ (1994) High attrition rate with intracavernous injection of prostaglandin E1 for impotency. Urology 43: 84-87
46. Ishii N, Watanabe H, Irisawa C, Kikushi Y (1986) Therapeutic trial with prostaglandin E1 for organic impotence. Proceedings, 2nd world meeting on impotence, Prague, October 13, 1986
47. Jantos C, Krause W, Kauss E, Weidner W (1988) [Long-term experiences with autoinjection therapy of papaverine in erectile dysfunction.] Urologe [A] 27: 18-21
48. Juenemann KP, Alken P (1989) Pharmacotherapy of erectile dysfunction: a review. Int J Impotence Res 1: 71-93
49. Jünemann KP, Alken P (1989) Pharmacotherapy of erectile dysfunction. Int J Impotence Res 1: 71-94
50. Jünemann KP, Lue TF, Fournier GF, Tanagho EA (1986) Hemodynamics of papaverine and phentolamine-indueed erections. J Urol 136: 158-161
51. Kiely EA, Ignotus P, Williams G (1987) Penile function following intracavernosal injection of vasoactive agents or saline. Br J Urol 59: 473-476
52. Kiely EA, Bloom SR, Williams G (1989) Penile response to intracavernosal VIP alone and in combination with other vasoactive agents. Br J Urol 64: 191
53. Kirkeby HJ, Petersen T, Poulsen EU (1988) Pharmacologically induced erection in patients with multiple sclerosis. Scand J Urol Nephrol 22: 241-244
54. Kirkeby HJ, Johannesen NL (1989) Pharmacologically induced prolonged erections produced by papaverine. Followup of injection therapy. Scand J Urol Nephrol [Suppl] 125: 97-100
55. Kirkeby HJ, Forman A, Andersson KE (1990) Comparison of the papaverine effects on isolated human penile circumflex veins and corpus cavernosum. Int J Impotence Res 2: 49-54
56. Klinge E, Sjöstrand HO (1974) Contraction and relaxation of the retractor penis muscle and the penile artery of the bull. Acta Physiol Scand [Suppl] 20: 420
57. Krall JF, Fittinghoff M, Rajfer J(1988) Characterization of cyclic nucleotide and inositol 1,4,5-triphosphate sensitive calcium-exchange activity of smooth muscle cells cultured from the human corpora cavernosa. Biol Reprod 39: 913-922
58. Laurenza A, McHugh Sutkowski E, Seamon KB (1989) Forskolin: a specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action? TIPS 10: 442-447
59. Levine SB, Althof SE, Turner LA, Risen CB, Bodner DR, Kursh ED, Resnick MI (1989) Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol 141: 54-57
60. Linet OI, Neff LL (1994) Intracavernous prostaglandin E1 in erectile dysfunction, Clin Invest 72: 139-149
61. Lue TF, Tanagho EA (1987) Physiology of erection and pharmacological management of impotence. J Urol 137: 829-836
62. Meyer MF, Taher A, Krah H, Staubesand J, Becker AJ, Kircher M, Mayer B, Jonas U, Forssmann WG, Stief CG (1993) Intracavernous application of SIN-I in rabbit and man: functional and toxicological results. Ann Urol (Paris) 27: 179-182
63. Molderings GJ, Ahlen H van, Göthert M (1992) Modulation of noradrenalin release in human corpus cavernosum by presynaptic prostaglandin receptors. Int J Impotence Res 4: 19-26
64. 63a. Montorsi F, Guazzoni G, Bergamaschi F, Dodesini A, Rigatti P, Pizzini G, Miani A (1993) Effectiveness and safety of multidrug therapy for vasculogenic impotence. Urology 42: 554 548
65. Nellans RE, Ellis LR, Kramer LD (1987) Pharmacological erection: diagnosis and treatment applications in 69 patients. J Urol 138: 52-54
66. Nelson RP (1989) Injections of papaverine and regitine into the corpora cavernosa for erectile dysfunction: clinical results in 60 patients. South Med J 82: 26-28
67. Nisen H (1993) Cavernous auto-injection therapy with prostaglandin E1. Ann Chir Gynaecol Suppl 206: 69-73
68. Padma-Nathan H (1990) The efficacy and synergy of polypharmaceutical intracavernosal pharmacotherapy. J Urol 143: 304A
69. Padma-Nathan H, Goldstein I, Payton T, Krane RJ (1987) Intracavernosal pharmacotherapy: the pharmacologic erection programme. World J Urol 5: 160-165
70. Padma-Nathan H, Bennett A, Gesundheit N, Hellstrom W, Henry D, Lue TF, Morley J, Peterson C, Prendergast JJ, Tam P, Teresi A, Place V (1995) Treatment of erectile dysfunction by the medicated urethral system for erection (MUSE). J Urol 153: 472A
71. Palmer LS, Valcic M, Giraldi AM, Wagner G, Christ GJ (1994) Characterization of cyclic AMP accumulation in cultured human corpus cavernosum smooth muscle cells. J Urol 152: 1308
72. Palmer RMJ, Ferrige AG, Moncada S (1987) Nitric oxide release accounts for the biological activity of endotheliumderived relaxing factor. Nature 327: 524-526
73. Paoletti R (1986) Biochemistry and pharmacology of prostaglandin E1: introductory remarks. In: Sinzinger H. Rogatti W (eds) Prostaglandin E1 in atherosclerosis. Springer, Berlin Heidelberg New York, pp 3-7
74. Porst H (1988) [Value of prostaglandin E1 in the diagnosis of erectile dysfunction in comparison with papaverine and papaverine/phentolamine in 61 patients with erectile dysfunction.] Urologe [A] 27: 22-26
75. Porst H (1989) [Prostaglandin E1 in erectile dysfunction.] Urologe [A] 28: 94-98
76. Porst H (1996) The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 155: 802-815
77. Porst H, Buvat J, Hauri D, Krotovsky GS, Meulemann EJH, Michal V, Wagner G, Wespes E (1994) Self-injection therapy with prostaglandin E1 - long-term results of an international multicenter study according to the GCP-standard. Int J Impotence Res 6: D108
78. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ (1992) Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 326: 90-94
79. Rajmil O, Garcia F, Fabian E, Bassas L, Pomerol JM (1997) [Prolonged erections after diagnostic injection of papaverine chlorhydrate.] Arch Esp Urol 44: 179-82
80. Reden J (1990) Molsidomine. Blood Vessels 27: 282-294
81. Richter S, Nissenkorn I (1994) Three years, 200 patients, 10,000 intracavernous self-injections with a triple-drug combination for the treatment of erectile dysfunction. Int J Impotence Res 6: D133
82. Robinette MA, Moffat MJ (1986) Intracorporal injection of papaverine and phentolamine in the management of impotence. Br J Urol 58: 692-695
83. Rudnick J, Jantos C, Kaub E, Herrmann D, Krause W, Weidner W (1988) Autoinjection of papaverine: experience with a pharmacological erection program in patients with erectile dysfunction. Proceedings, 3rd Biennial world meeting on impotence, Boston, October 6, 1988, p 173
84. Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA (1989) Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 320: 1025-1030
85. Schramek P, Dorninger R, Waldhauser M, Konecny P, Porpaczy P (1990) Prostaglandin E1 in erectile dysfunction. Efficiency and incidence of priapism. Br J Urol 65: 68-71
86. Seamon KB (1984) Forskolin and adenylate cyclase: new opportunities in drug design. Annu Rep Med Chem 19: 293
87. Sidi AA, Chen KK (1987) Clinical experience with vasoactive intracavernous pharmacotherapy for the treatment of impotence. World J Urol 5: 156-159
88. Stackl W, Hasun R, Marberger M (1988) Intracavernous injection of prostaelandin E1 in impotent men. J Urol 140: 6668
89. Steffens J, Postma H, Steffens L (1988) Ergebnisse und Akzeptant der Schwellkörperautoinjektionstherapie (SKAT) bei organischer erektiler Dysfunktion. Urologe [A] 27: 14-16
90. Stief CG, Bahren W, Beckert R, Altwein JE (1986) [Preliminary results of the treatment of erectile impotence by intracavernous self administration of vasoactive substances.] J Urol Paris 92: 349-351
91. Stief CG, Gall H, Scherb W, Bahren W (1988) Mid-term results of autoinjection therapy for erectile dysfunction. Urology 31: 483-485
92. Stief CG, Wetterauer U, Schaebsdau FH, Jonas U (1991) Calcitonin-gene-related peptide: a possible role in human penile erection and its therapeutic application in impotent patients, J Urol 146: 1010-1014
93. Stief CG, Holmquist F, Djamilian M, Krah H, Andersson KE, Jonas U (1992) Preliminary results with the nitric oxide donor linsidomine chlorhydrate in the treatment of human erectile dysfunction. J Urol 148: 1437-1440
94. Stief CG, Benard F, Bosch R, Aboseif S, Wetterauer U, Lue TF, Tanagho EA (1993) Calcitonin gene-related peptide: possibly neurotransmitter contributes to penile erection in monkeys. Urology 41: 397-401
95. Thon WF, Hartmann U (1993) [Effectiveness and safety of cavernous body auto-injection therapy with papaverine/ phentolamine: study group.] Urologe [A] 32: 466-469
96. Trigo Rocha F, Donatucci CF, Hsu GL, Nunes L, Lue TF, Tanagho EA (1995) The effect of intracavernous injection of potassium channel openers in monkeys and dogs. Int J Impot Res 7: 41-48
97. Truss MC, Becker AJ, Djamilian MH, Stief CG, Jonas U 1994) The role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction. Urology 44: 553-556
98. Truss MC, Becker AJ, Thon WF, Kuczyk M, Djamilian MH, Stief CG, Jonas U (1994) Intracavernous culcitonin gene-related peptide plus prostaglandin E1: possible alternative to penile implants in selected patients. Eur Urol 26: 40-45
99. Virag R (1982) Intracavernous injection of papaverine for erectile failure (letter to the editor). Lancet II: 938
100. Virag R (1985) About pharmacologically induced prolonged erection (letter). Lancet I: 519-520
101. Virag R, Daniel C, Sussmann H, Bouilly P, Virag H (1986) Selfintracavernous injection of vasoactive drugs for the treatment of psychogenic and neurologic impotence (late results in 109 patients). Proceedings, 5th conference on vasculogenic impotence and corpus cavernosum revascularization; 2nd world meeting on impotence. October 13, 1986, Prague, p 11.1
102. Virag R, Sussmann H, Floresco J, Shouler K (1987) Late results on the treatment of neurogenic impotence by self-intracavernous injection (SICI) of vasoactive drugs. World J Urol 5: 166-170
103. Virag R, Nollet F, Greco E, Floresco J (1994) Long term evaluation of local complications of self intracavernous injections (SICI). Int J Impotence Res 6: A37
104. Von Heyden B, Brock GB, Lue TF (1995) No SIN1 toxicity found in monkeys following long term intracavernous administration. J Urol [Suppl] 153: 440A
105. Wagner G, Gerstenberg T (1988) Vasoactive intestinal polypeptide facilitates normal erection, Proceedings, 3rd biennial world meeting on impotence, Boston, October 6. 1988, p 146
106. Waldhauser M, Schramek P (1988) Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction. J Urol 140: 525-527
107. Wetterauer U (1991) Intracavernous pharmacotherapy for erectile dysfunction. In: Jonas U, Thon WF, Stief CG (eds) Erectile dysfunction. Springer, Berlin Heidelberg New York. pp 221-235
108. Williams G, Mulcahy MJ, Kiely EA (1987) Impotence: treatment by autoinjection of vasoactive drugs. Br Med J Clin Res 295: 595-596
109. Zorgniotti AW (1986) Corpus cavernosum blockade for impotence: practical aspects and results in 250 cases. J Urol 135: 306A
110. Zorgniotti AW, Lefleur RS (1985) Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. J Urol 133: 39-41